Skip to content
Reyvow, Rayvow(lasmiditan)
Rayvow, Reyvow (lasmiditan) is a small molecule pharmaceutical. Lasmiditan was first approved as Reyvow on 2020-01-31. It is used to treat migraine with aura and migraine without aura in the USA. It has been approved in Europe to treat migraine disorders. It is known to target 5-hydroxytryptamine receptor 1F.
Download report
Favorite
FDA Novel Drug Approvals 2019
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
Trade Name
FDA
EMA
Reyvow
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lasmiditan succinate
Tradename
Company
Number
Date
Products
REYVOWEli LillyN-211280 RX2020-01-31
2 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
reyvowExport only2023-01-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
migraine with auraEFO_0005295D020325G43.1
migraine without auraEFO_0005296D020326G43.0
Agency Specific
FDA
EMA
Expiration
Code
LASMIDITAN SUCCINATE, REYVOW, ELI LILLY AND CO
2025-01-31NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Lasmiditan Succinate, Reyvow, Eli Lilly And Co
110532142037-12-05DS, DPU-1719
74230502024-03-27DS, DPU-1719
87484592023-03-27U-1719
ATC Codes
N: Nervous system drugs
— N02: Analgesics
— N02C: Antimigraine preparations
— N02CC: Selective serotonin (5ht1) agonists
— N02CC08: Lasmiditan
HCPCS
No data
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Migraine disordersD008881EFO_0003821G43635——14
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—15————15
Recreational drug useD0000847831————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLASMIDITAN
INNlasmiditan
Description
Lasmiditan, sold under the brand name Reyvow, is a medication used for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. It is not useful for prevention. It is taken by mouth.
Classification
Small molecule
Drug classantimigraine, serotonin 5-HT1 receptor agonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1
Identifiers
PDB—
CAS-ID439239-90-4
RxCUI—
ChEMBL IDCHEMBL3039520
ChEBI ID—
PubChem CID11610526
DrugBankDB11732
UNII ID760I9WM792 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
HTR1F
HTR1F
Organism
Homo sapiens
Gene name
HTR1F
Gene synonyms
HTR1EL
NCBI Gene ID
3355
Protein name
5-hydroxytryptamine receptor 1F
Protein synonyms
5-hydroxytryptamine (serotonin) receptor 1F, G protein-coupled, Serotonin receptor 1F
Uniprot ID
P30939
Mouse ortholog
Htr1f (15557)
5-hydroxytryptamine receptor 1F (Q02284)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 302 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,421 adverse events reported
View more details